DigestRedComo funciona
Red
/
Empresas
Bl
No verificado

BlossomHill Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaOncologíaSalud

3 Comunicados de prensa

Ver todos los comunicados de prensa
03/04/2025
Eventos
Industria
Biotecnología
Farmacéutica
Salud
Oncología
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting
Fuente
BlossomHill Therapeutics, Inc.
Editor
Business Wire
1.00
0
22/01/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer
Fuente
BlossomHill Therapeutics, Inc.
Editor
Business Wire
1.00
0
06/01/2025
Mercado laboral
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President
Fuente
BlossomHill Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0